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A 35-year-old female presented with acute 
abdominal pain in the epigastric and left 
hypochondriac region since last three days. She 
also reported associated vomiting and fever. She 
initially went to a general practitioner where she 
was diagnosed as having colitis with the help of 
ultrasonography abdomen. She did not improve 
with routine medication. Therefore, she was 
referred to us and we ordered routine blood 
investigations. She is nondiabetic, and her thyroid 
profile was standard. Her family and personal 
history for hyperlipidemia were non-significant. 
Her BMI was 25 kg/m2. At the outset, we did not 
suspect pancreatitis as the pain was not typical of 
pancreatitis and we had ultrasound diagnosis of 
colitis. Serum became lipemic after 10 min of 
collection (Figure 1). 
 
 
Prompt diagnosis of acute pancreatitis came to our 
mind. We ordered further investigations to rule out 
hyperlipidemia and pancreatitis. Her serum 
amylase was 350 IU/L, lipase 3800U/L, serum 
cholesterol 835mg/dL and, serum triglyceride 
958mg/dL. Diagnosis of acute pancreatitis 
secondary to hypertriglyceridemia was made. We 
ordered computed tomography of the abdomen, 
which confirmed the diagnosis of pancreatitis. She 
was treated with conservative management and 
discharged on the 5th day of hospitalization in good 
health. She was started on lipid-lowering agents 
(statins). She is on regular follow up since last six 
months without recurrence, and her lipid profile is 
within the normal range at present. 
Hyperlipidemia is an uncommon cause of acute 
pancreatitis and accounts for 2 to 5% cases1. Serum 
triglycerides (TGs) level >500 mg/dl increase the 
risk of acute pancreatitis2. However, the risk 
increases with increase in TGs level [>1000 mg/dL 
(5%) and >2000 mg/dL (10%)]2. Although the 
mechanisms involved in the pathogenesis of acute 
pancreatitis secondary to hypertriglyceridemia are 
not entirely understood, the release of large 
amounts of fatty acids by lipase inhibited 
mitochondrial complexes I and V and decreased 
ATP levels in acinar cells, which induced 
mitochondrial toxicity in pancreatic acinar cells are 
implicated3. The endothelial lining of small 
pancreatic blood vessels is the first target of the 
injury4. Therefore, Angiopoietin-2 has been 
recently proposed as a marker of severity in acute 
pancreatitis5. Free fatty acids can directly injure the 
membrane by inducing free radical damage1. 
Hyperlipidemic pancreatitis may be associated with 
average serum amylase level but elevated serum 
lipase as in our case4. Suppression of amylase 
activity by lipemic serum or a non-lipid factor in 
the circulation is responsible for normal amylase 
level in hyperlipidemic pancreatitis6,7. The clinical 
features are similar to pancreatitis associated with 
other etiologies. Treatment is usually supportive 
care. Sometimes patients with severe 
hypertriglyceridemia (>10,000 mg/dl) may be 
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benefited by Plasmapheresis to reduce circulating 
TGs levels4. Once patients recover, low-fat diet 
forms the mainstay of therapy4. Antihyperlipidemic 
agents may be indicated in some cases1. 
Plasmapheresis lowers the TGs level in the setting 
of hyperlipidemic pancreatitis, but it does not affect 
the overall morbidity and mortality8. Gene therapy 
is a novel target treatment for hyperlipidemic 
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